Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 February 2007, Vol. 109, No. 3, pp. 1244-1247.
Prepublished online as a Blood First Edition Paper on October 17, 2006; DOI 10.1182/blood-2006-02-002915.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-02-002915v1
109/3/1244    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benjamin, R.
Right arrow Articles by Nathwani, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benjamin, R.
Right arrow Articles by Nathwani, A. C.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Immunotherapy
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Brief Report

Continuous delivery of human type I interferons ({alpha}/ß) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model

Reuben Benjamin1, Asim Khwaja1, Nalini Singh1, Jenny McIntosh1, Anthony Meager2, Meenu Wadhwa2, Christian Streck3, Catherine Ng3, Andrew M. Davidoff3, and Amit C. Nathwani1,4

1 Department of Haematology, University College London, United Kingdom; 2 Division of Immunology and Endocrinology, National Institute for Biological Standards and Control, Herts, United Kingdom; 3 Division of Experimental Hematology and Department of Surgery, St Jude Children's Research Hospital, Memphis, TN; 4 National Blood Service, London, United Kingdom

In this study, we focused primarily on the antileukemic activity of interferon-ß (IFN-ß) in a murine xenograft model of acute myeloid leukemia (AML). Bolus administration of recombinant IFN-ß via the subcutaneous or intravenous route failed to show efficacy in mice injected with AML cells despite achieving peak plasma IFN-ß levels of more than 200 IU/mL. In contrast, stable expression of IFN-ß following adeno-associated virus (AAV) vector–mediated gene transfer resulted in significant antileukemic activity against primary AML cells derived from patients with poor prognostic markers. An almost linear relationship was observed with stable plasma levels of IFN-ß and antileukemic activity in mice. Even levels below 10 IU/mL were able to reduce tumor load by 50-fold when compared with control animals. These levels of IFN-ß are likely to be nontoxic in humans. Therefore, approaches capable of maintaining stable plasma levels of IFN-ß merit further clinical evaluation in patients with AML.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020